Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real‐world evidence
Body mass index (BMI) is a main indicator of obesity and its association with breast cancer is well established. However, little is known in the metastatic setting, especially in HER2‐positive patients. We assessed the influence of BMI on clinical outcomes of patients treated with pertuzumab and/or...
Gespeichert in:
| Veröffentlicht in: | Journal of cellular physiology 2020-11, Vol.235 (11), p.7900-7910 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 7910 |
|---|---|
| container_issue | 11 |
| container_start_page | 7900 |
| container_title | Journal of cellular physiology |
| container_volume | 235 |
| creator | Krasniqi, Eriseld Pizzuti, Laura Barchiesi, Giacomo Sergi, Domenico Carpano, Silvia Botti, Claudio Kayal, Ramy Sanguineti, Giuseppe Marchetti, Paolo Botticelli, Andrea Marinelli, Daniele Gamucci, Teresa Natoli, Clara Grassadonia, Antonino Tinari, Nicola Tomao, Silverio Tonini, Giuseppe Santini, Daniele Michelotti, Aandrea Mentuccia, Lucia Vaccaro, Aangela Magnolfi, Emanuela Gelibter, Alain Magri, Valentina Cortesi, Enrico D’Onofrio, Loretta Cassano, Alessandra Cazzaniga, Marina Moscetti, Luca Fabbri, Agnese Scinto, Angelo Fedele Corsi, Domenico Carbognin, Luisa Bria, Emilio La Verde, Nicla Garufi, Carlo Di Stefano, Pia Mirabelli, Rossana Veltri, Enzo Paris, Ida Giotta, Francesco Lorusso, Vito Landucci, Elisa Ficorella, Corrado Roselli, Mario Adamo, Vincenzo Ricciardi, Giuseppina Russo, Antonio Valerio, Maria Rosaria Berardi, Rossana Pistelli, Mirco Cannita, Katia Zamagni, Claudio Garrone, Ornella Baldini, Editta Livi, Lorenzo Meattini, Icro Del Medico, Pietro Generali, Daniele De Maria, Ruggero Risi, Emanuela Ciliberto, Gennaro Villa, Alice Sperduti, Isabella Mazzotta, Marco Barba, Maddalena Giordano, Antonio Vici, Patrizia |
| description | Body mass index (BMI) is a main indicator of obesity and its association with breast cancer is well established. However, little is known in the metastatic setting, especially in HER2‐positive patients. We assessed the influence of BMI on clinical outcomes of patients treated with pertuzumab and/or trastuzumab emtansine (T‐DM1) for HER2+ metastatic breast cancer (mBC). BMI was addressed as a categorical variable, being classified on the basis of the following ranges, that is, 18.5–24.9, 25–29.9, and 30.0–34.9, namely, normal weight, overweight, and Class I obesity. The outcomes chosen were progression‐free survival to first‐line chemotherapy (PFS1) and overall survival (OS). Overall (N = 709), no impact of BMI was observed on PFS1 (p = .15), while BMI ≥ 30 was associated with worse OS (p = .003). In subjects who progressed to first line (N = 575), analyzing data across PFS1 quartiles and strata of disease burden, BMI predicted lower PFS1 in patients within the I PFS1 quartile and with the lowest disease burden (p = .001). Univariate analysis showed a detrimental effect of BMI ≥ 30 on OS for women within the I PFS1 quartile (p = .03). Results were confirmed in multivariate analysis. According to PFS1 quartiles a higher percentage of patients with high BMI and low disease burden progressed within 6 months of therapy. The effect of BMI on prognosis was also confirmed in multivariate analysis of OS for overall population. In our cohort, a BMI ≥ 30 correlated with worse OS in patients with HER2+ mBC who received pertuzumab and/or T‐DM1 but had no impact on PFS to first line. BMI predicted worse I PFS1 quartile.
We found that a body mass index ≥ 30 correlates with worse overall survival in HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine but had no impact on progression‐free survival (PFS) to first line. BMI predicted worse I PFS1 quartile. |
| doi_str_mv | 10.1002/jcp.29445 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2444769363</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2444769363</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3535-aef57d2aeff3c09912eb9c484ba8adc6f203c925910b8eb88b92913fc2ae158b3</originalsourceid><addsrcrecordid>eNp1kE1OwzAQhS0EglJYcAFkiRVCaf2XJl5CVaAIBEKwjmxnIlI1P9gOVVmx4ACckZNgaGHHakZvvnmjeQgdUDKghLDhzLQDJoWIN1CPEplEYhSzTdQLMxrJWNAdtOvcjBAiJefbaIdTKThNaA-9T6tWGY-bAp_dTHFT48vJPTvBFXjlvPKlwdpCaLFRtQGL26BB7R32QfaQ40Xpn3AL1nevXaU0VnU-bGwYh6W1BJVXtStrGOB7UPPPt49FY-c5hpcyh-C6h7YKNXewv6599Hg-eRhfRte3F9Px6XVkeMzjSEERJzkLpeAmvEIZaGlEKrRKVW5GBSPcSBZLSnQKOk21ZJLywoQVGqea99HRyre1zXMHzmezprN1OJkxIUQyknzEA3W8ooxtnLNQZK0tK2WXGSXZd95ZyDv7yTuwh2vHTleQ_5G_AQdguAIW5RyW_ztlV-O7leUXPMCMSg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2444769363</pqid></control><display><type>article</type><title>Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real‐world evidence</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Krasniqi, Eriseld ; Pizzuti, Laura ; Barchiesi, Giacomo ; Sergi, Domenico ; Carpano, Silvia ; Botti, Claudio ; Kayal, Ramy ; Sanguineti, Giuseppe ; Marchetti, Paolo ; Botticelli, Andrea ; Marinelli, Daniele ; Gamucci, Teresa ; Natoli, Clara ; Grassadonia, Antonino ; Tinari, Nicola ; Tomao, Silverio ; Tonini, Giuseppe ; Santini, Daniele ; Michelotti, Aandrea ; Mentuccia, Lucia ; Vaccaro, Aangela ; Magnolfi, Emanuela ; Gelibter, Alain ; Magri, Valentina ; Cortesi, Enrico ; D’Onofrio, Loretta ; Cassano, Alessandra ; Cazzaniga, Marina ; Moscetti, Luca ; Fabbri, Agnese ; Scinto, Angelo Fedele ; Corsi, Domenico ; Carbognin, Luisa ; Bria, Emilio ; La Verde, Nicla ; Garufi, Carlo ; Di Stefano, Pia ; Mirabelli, Rossana ; Veltri, Enzo ; Paris, Ida ; Giotta, Francesco ; Lorusso, Vito ; Landucci, Elisa ; Ficorella, Corrado ; Roselli, Mario ; Adamo, Vincenzo ; Ricciardi, Giuseppina ; Russo, Antonio ; Valerio, Maria Rosaria ; Berardi, Rossana ; Pistelli, Mirco ; Cannita, Katia ; Zamagni, Claudio ; Garrone, Ornella ; Baldini, Editta ; Livi, Lorenzo ; Meattini, Icro ; Del Medico, Pietro ; Generali, Daniele ; De Maria, Ruggero ; Risi, Emanuela ; Ciliberto, Gennaro ; Villa, Alice ; Sperduti, Isabella ; Mazzotta, Marco ; Barba, Maddalena ; Giordano, Antonio ; Vici, Patrizia</creator><creatorcontrib>Krasniqi, Eriseld ; Pizzuti, Laura ; Barchiesi, Giacomo ; Sergi, Domenico ; Carpano, Silvia ; Botti, Claudio ; Kayal, Ramy ; Sanguineti, Giuseppe ; Marchetti, Paolo ; Botticelli, Andrea ; Marinelli, Daniele ; Gamucci, Teresa ; Natoli, Clara ; Grassadonia, Antonino ; Tinari, Nicola ; Tomao, Silverio ; Tonini, Giuseppe ; Santini, Daniele ; Michelotti, Aandrea ; Mentuccia, Lucia ; Vaccaro, Aangela ; Magnolfi, Emanuela ; Gelibter, Alain ; Magri, Valentina ; Cortesi, Enrico ; D’Onofrio, Loretta ; Cassano, Alessandra ; Cazzaniga, Marina ; Moscetti, Luca ; Fabbri, Agnese ; Scinto, Angelo Fedele ; Corsi, Domenico ; Carbognin, Luisa ; Bria, Emilio ; La Verde, Nicla ; Garufi, Carlo ; Di Stefano, Pia ; Mirabelli, Rossana ; Veltri, Enzo ; Paris, Ida ; Giotta, Francesco ; Lorusso, Vito ; Landucci, Elisa ; Ficorella, Corrado ; Roselli, Mario ; Adamo, Vincenzo ; Ricciardi, Giuseppina ; Russo, Antonio ; Valerio, Maria Rosaria ; Berardi, Rossana ; Pistelli, Mirco ; Cannita, Katia ; Zamagni, Claudio ; Garrone, Ornella ; Baldini, Editta ; Livi, Lorenzo ; Meattini, Icro ; Del Medico, Pietro ; Generali, Daniele ; De Maria, Ruggero ; Risi, Emanuela ; Ciliberto, Gennaro ; Villa, Alice ; Sperduti, Isabella ; Mazzotta, Marco ; Barba, Maddalena ; Giordano, Antonio ; Vici, Patrizia</creatorcontrib><description>Body mass index (BMI) is a main indicator of obesity and its association with breast cancer is well established. However, little is known in the metastatic setting, especially in HER2‐positive patients. We assessed the influence of BMI on clinical outcomes of patients treated with pertuzumab and/or trastuzumab emtansine (T‐DM1) for HER2+ metastatic breast cancer (mBC). BMI was addressed as a categorical variable, being classified on the basis of the following ranges, that is, 18.5–24.9, 25–29.9, and 30.0–34.9, namely, normal weight, overweight, and Class I obesity. The outcomes chosen were progression‐free survival to first‐line chemotherapy (PFS1) and overall survival (OS). Overall (N = 709), no impact of BMI was observed on PFS1 (p = .15), while BMI ≥ 30 was associated with worse OS (p = .003). In subjects who progressed to first line (N = 575), analyzing data across PFS1 quartiles and strata of disease burden, BMI predicted lower PFS1 in patients within the I PFS1 quartile and with the lowest disease burden (p = .001). Univariate analysis showed a detrimental effect of BMI ≥ 30 on OS for women within the I PFS1 quartile (p = .03). Results were confirmed in multivariate analysis. According to PFS1 quartiles a higher percentage of patients with high BMI and low disease burden progressed within 6 months of therapy. The effect of BMI on prognosis was also confirmed in multivariate analysis of OS for overall population. In our cohort, a BMI ≥ 30 correlated with worse OS in patients with HER2+ mBC who received pertuzumab and/or T‐DM1 but had no impact on PFS to first line. BMI predicted worse I PFS1 quartile.
We found that a body mass index ≥ 30 correlates with worse overall survival in HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine but had no impact on progression‐free survival (PFS) to first line. BMI predicted worse I PFS1 quartile.</description><identifier>ISSN: 0021-9541</identifier><identifier>EISSN: 1097-4652</identifier><identifier>DOI: 10.1002/jcp.29445</identifier><identifier>PMID: 31943171</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Ado-Trastuzumab Emtansine - therapeutic use ; Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Humanized - therapeutic use ; Antineoplastic Agents, Immunological - therapeutic use ; Body Mass Index ; Body size ; Body weight ; Breast cancer ; Breast Neoplasms - drug therapy ; Breast Neoplasms - genetics ; Breast Neoplasms - mortality ; Chemotherapy ; Disease Progression ; ErbB-2 protein ; Female ; HER2‐positive metastatic breast cancer ; Humans ; Immunotherapy ; Medical prognosis ; Metastases ; Metastasis ; Middle Aged ; Monoclonal antibodies ; Multivariate analysis ; Obesity ; Obesity - complications ; Overweight ; Overweight - complications ; pertuzumab ; Progression-Free Survival ; Quartiles ; Receptor, ErbB-2 - genetics ; Survival ; Targeted cancer therapy ; Trastuzumab ; trastuzumab emtansine</subject><ispartof>Journal of cellular physiology, 2020-11, Vol.235 (11), p.7900-7910</ispartof><rights>2020 Wiley Periodicals, Inc.</rights><rights>2020 Wiley Periodicals LLC</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3535-aef57d2aeff3c09912eb9c484ba8adc6f203c925910b8eb88b92913fc2ae158b3</citedby><cites>FETCH-LOGICAL-c3535-aef57d2aeff3c09912eb9c484ba8adc6f203c925910b8eb88b92913fc2ae158b3</cites><orcidid>0000-0001-7528-9783 ; 0000-0003-4353-5390 ; 0000-0001-9050-2917</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjcp.29445$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjcp.29445$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31943171$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Krasniqi, Eriseld</creatorcontrib><creatorcontrib>Pizzuti, Laura</creatorcontrib><creatorcontrib>Barchiesi, Giacomo</creatorcontrib><creatorcontrib>Sergi, Domenico</creatorcontrib><creatorcontrib>Carpano, Silvia</creatorcontrib><creatorcontrib>Botti, Claudio</creatorcontrib><creatorcontrib>Kayal, Ramy</creatorcontrib><creatorcontrib>Sanguineti, Giuseppe</creatorcontrib><creatorcontrib>Marchetti, Paolo</creatorcontrib><creatorcontrib>Botticelli, Andrea</creatorcontrib><creatorcontrib>Marinelli, Daniele</creatorcontrib><creatorcontrib>Gamucci, Teresa</creatorcontrib><creatorcontrib>Natoli, Clara</creatorcontrib><creatorcontrib>Grassadonia, Antonino</creatorcontrib><creatorcontrib>Tinari, Nicola</creatorcontrib><creatorcontrib>Tomao, Silverio</creatorcontrib><creatorcontrib>Tonini, Giuseppe</creatorcontrib><creatorcontrib>Santini, Daniele</creatorcontrib><creatorcontrib>Michelotti, Aandrea</creatorcontrib><creatorcontrib>Mentuccia, Lucia</creatorcontrib><creatorcontrib>Vaccaro, Aangela</creatorcontrib><creatorcontrib>Magnolfi, Emanuela</creatorcontrib><creatorcontrib>Gelibter, Alain</creatorcontrib><creatorcontrib>Magri, Valentina</creatorcontrib><creatorcontrib>Cortesi, Enrico</creatorcontrib><creatorcontrib>D’Onofrio, Loretta</creatorcontrib><creatorcontrib>Cassano, Alessandra</creatorcontrib><creatorcontrib>Cazzaniga, Marina</creatorcontrib><creatorcontrib>Moscetti, Luca</creatorcontrib><creatorcontrib>Fabbri, Agnese</creatorcontrib><creatorcontrib>Scinto, Angelo Fedele</creatorcontrib><creatorcontrib>Corsi, Domenico</creatorcontrib><creatorcontrib>Carbognin, Luisa</creatorcontrib><creatorcontrib>Bria, Emilio</creatorcontrib><creatorcontrib>La Verde, Nicla</creatorcontrib><creatorcontrib>Garufi, Carlo</creatorcontrib><creatorcontrib>Di Stefano, Pia</creatorcontrib><creatorcontrib>Mirabelli, Rossana</creatorcontrib><creatorcontrib>Veltri, Enzo</creatorcontrib><creatorcontrib>Paris, Ida</creatorcontrib><creatorcontrib>Giotta, Francesco</creatorcontrib><creatorcontrib>Lorusso, Vito</creatorcontrib><creatorcontrib>Landucci, Elisa</creatorcontrib><creatorcontrib>Ficorella, Corrado</creatorcontrib><creatorcontrib>Roselli, Mario</creatorcontrib><creatorcontrib>Adamo, Vincenzo</creatorcontrib><creatorcontrib>Ricciardi, Giuseppina</creatorcontrib><creatorcontrib>Russo, Antonio</creatorcontrib><creatorcontrib>Valerio, Maria Rosaria</creatorcontrib><creatorcontrib>Berardi, Rossana</creatorcontrib><creatorcontrib>Pistelli, Mirco</creatorcontrib><creatorcontrib>Cannita, Katia</creatorcontrib><creatorcontrib>Zamagni, Claudio</creatorcontrib><creatorcontrib>Garrone, Ornella</creatorcontrib><creatorcontrib>Baldini, Editta</creatorcontrib><creatorcontrib>Livi, Lorenzo</creatorcontrib><creatorcontrib>Meattini, Icro</creatorcontrib><creatorcontrib>Del Medico, Pietro</creatorcontrib><creatorcontrib>Generali, Daniele</creatorcontrib><creatorcontrib>De Maria, Ruggero</creatorcontrib><creatorcontrib>Risi, Emanuela</creatorcontrib><creatorcontrib>Ciliberto, Gennaro</creatorcontrib><creatorcontrib>Villa, Alice</creatorcontrib><creatorcontrib>Sperduti, Isabella</creatorcontrib><creatorcontrib>Mazzotta, Marco</creatorcontrib><creatorcontrib>Barba, Maddalena</creatorcontrib><creatorcontrib>Giordano, Antonio</creatorcontrib><creatorcontrib>Vici, Patrizia</creatorcontrib><title>Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real‐world evidence</title><title>Journal of cellular physiology</title><addtitle>J Cell Physiol</addtitle><description>Body mass index (BMI) is a main indicator of obesity and its association with breast cancer is well established. However, little is known in the metastatic setting, especially in HER2‐positive patients. We assessed the influence of BMI on clinical outcomes of patients treated with pertuzumab and/or trastuzumab emtansine (T‐DM1) for HER2+ metastatic breast cancer (mBC). BMI was addressed as a categorical variable, being classified on the basis of the following ranges, that is, 18.5–24.9, 25–29.9, and 30.0–34.9, namely, normal weight, overweight, and Class I obesity. The outcomes chosen were progression‐free survival to first‐line chemotherapy (PFS1) and overall survival (OS). Overall (N = 709), no impact of BMI was observed on PFS1 (p = .15), while BMI ≥ 30 was associated with worse OS (p = .003). In subjects who progressed to first line (N = 575), analyzing data across PFS1 quartiles and strata of disease burden, BMI predicted lower PFS1 in patients within the I PFS1 quartile and with the lowest disease burden (p = .001). Univariate analysis showed a detrimental effect of BMI ≥ 30 on OS for women within the I PFS1 quartile (p = .03). Results were confirmed in multivariate analysis. According to PFS1 quartiles a higher percentage of patients with high BMI and low disease burden progressed within 6 months of therapy. The effect of BMI on prognosis was also confirmed in multivariate analysis of OS for overall population. In our cohort, a BMI ≥ 30 correlated with worse OS in patients with HER2+ mBC who received pertuzumab and/or T‐DM1 but had no impact on PFS to first line. BMI predicted worse I PFS1 quartile.
We found that a body mass index ≥ 30 correlates with worse overall survival in HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine but had no impact on progression‐free survival (PFS) to first line. BMI predicted worse I PFS1 quartile.</description><subject>Ado-Trastuzumab Emtansine - therapeutic use</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antibodies, Monoclonal, Humanized - therapeutic use</subject><subject>Antineoplastic Agents, Immunological - therapeutic use</subject><subject>Body Mass Index</subject><subject>Body size</subject><subject>Body weight</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - genetics</subject><subject>Breast Neoplasms - mortality</subject><subject>Chemotherapy</subject><subject>Disease Progression</subject><subject>ErbB-2 protein</subject><subject>Female</subject><subject>HER2‐positive metastatic breast cancer</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Medical prognosis</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Monoclonal antibodies</subject><subject>Multivariate analysis</subject><subject>Obesity</subject><subject>Obesity - complications</subject><subject>Overweight</subject><subject>Overweight - complications</subject><subject>pertuzumab</subject><subject>Progression-Free Survival</subject><subject>Quartiles</subject><subject>Receptor, ErbB-2 - genetics</subject><subject>Survival</subject><subject>Targeted cancer therapy</subject><subject>Trastuzumab</subject><subject>trastuzumab emtansine</subject><issn>0021-9541</issn><issn>1097-4652</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kE1OwzAQhS0EglJYcAFkiRVCaf2XJl5CVaAIBEKwjmxnIlI1P9gOVVmx4ACckZNgaGHHakZvvnmjeQgdUDKghLDhzLQDJoWIN1CPEplEYhSzTdQLMxrJWNAdtOvcjBAiJefbaIdTKThNaA-9T6tWGY-bAp_dTHFT48vJPTvBFXjlvPKlwdpCaLFRtQGL26BB7R32QfaQ40Xpn3AL1nevXaU0VnU-bGwYh6W1BJVXtStrGOB7UPPPt49FY-c5hpcyh-C6h7YKNXewv6599Hg-eRhfRte3F9Px6XVkeMzjSEERJzkLpeAmvEIZaGlEKrRKVW5GBSPcSBZLSnQKOk21ZJLywoQVGqea99HRyre1zXMHzmezprN1OJkxIUQyknzEA3W8ooxtnLNQZK0tK2WXGSXZd95ZyDv7yTuwh2vHTleQ_5G_AQdguAIW5RyW_ztlV-O7leUXPMCMSg</recordid><startdate>202011</startdate><enddate>202011</enddate><creator>Krasniqi, Eriseld</creator><creator>Pizzuti, Laura</creator><creator>Barchiesi, Giacomo</creator><creator>Sergi, Domenico</creator><creator>Carpano, Silvia</creator><creator>Botti, Claudio</creator><creator>Kayal, Ramy</creator><creator>Sanguineti, Giuseppe</creator><creator>Marchetti, Paolo</creator><creator>Botticelli, Andrea</creator><creator>Marinelli, Daniele</creator><creator>Gamucci, Teresa</creator><creator>Natoli, Clara</creator><creator>Grassadonia, Antonino</creator><creator>Tinari, Nicola</creator><creator>Tomao, Silverio</creator><creator>Tonini, Giuseppe</creator><creator>Santini, Daniele</creator><creator>Michelotti, Aandrea</creator><creator>Mentuccia, Lucia</creator><creator>Vaccaro, Aangela</creator><creator>Magnolfi, Emanuela</creator><creator>Gelibter, Alain</creator><creator>Magri, Valentina</creator><creator>Cortesi, Enrico</creator><creator>D’Onofrio, Loretta</creator><creator>Cassano, Alessandra</creator><creator>Cazzaniga, Marina</creator><creator>Moscetti, Luca</creator><creator>Fabbri, Agnese</creator><creator>Scinto, Angelo Fedele</creator><creator>Corsi, Domenico</creator><creator>Carbognin, Luisa</creator><creator>Bria, Emilio</creator><creator>La Verde, Nicla</creator><creator>Garufi, Carlo</creator><creator>Di Stefano, Pia</creator><creator>Mirabelli, Rossana</creator><creator>Veltri, Enzo</creator><creator>Paris, Ida</creator><creator>Giotta, Francesco</creator><creator>Lorusso, Vito</creator><creator>Landucci, Elisa</creator><creator>Ficorella, Corrado</creator><creator>Roselli, Mario</creator><creator>Adamo, Vincenzo</creator><creator>Ricciardi, Giuseppina</creator><creator>Russo, Antonio</creator><creator>Valerio, Maria Rosaria</creator><creator>Berardi, Rossana</creator><creator>Pistelli, Mirco</creator><creator>Cannita, Katia</creator><creator>Zamagni, Claudio</creator><creator>Garrone, Ornella</creator><creator>Baldini, Editta</creator><creator>Livi, Lorenzo</creator><creator>Meattini, Icro</creator><creator>Del Medico, Pietro</creator><creator>Generali, Daniele</creator><creator>De Maria, Ruggero</creator><creator>Risi, Emanuela</creator><creator>Ciliberto, Gennaro</creator><creator>Villa, Alice</creator><creator>Sperduti, Isabella</creator><creator>Mazzotta, Marco</creator><creator>Barba, Maddalena</creator><creator>Giordano, Antonio</creator><creator>Vici, Patrizia</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7U7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>K9.</scope><scope>P64</scope><scope>RC3</scope><orcidid>https://orcid.org/0000-0001-7528-9783</orcidid><orcidid>https://orcid.org/0000-0003-4353-5390</orcidid><orcidid>https://orcid.org/0000-0001-9050-2917</orcidid></search><sort><creationdate>202011</creationdate><title>Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real‐world evidence</title><author>Krasniqi, Eriseld ; Pizzuti, Laura ; Barchiesi, Giacomo ; Sergi, Domenico ; Carpano, Silvia ; Botti, Claudio ; Kayal, Ramy ; Sanguineti, Giuseppe ; Marchetti, Paolo ; Botticelli, Andrea ; Marinelli, Daniele ; Gamucci, Teresa ; Natoli, Clara ; Grassadonia, Antonino ; Tinari, Nicola ; Tomao, Silverio ; Tonini, Giuseppe ; Santini, Daniele ; Michelotti, Aandrea ; Mentuccia, Lucia ; Vaccaro, Aangela ; Magnolfi, Emanuela ; Gelibter, Alain ; Magri, Valentina ; Cortesi, Enrico ; D’Onofrio, Loretta ; Cassano, Alessandra ; Cazzaniga, Marina ; Moscetti, Luca ; Fabbri, Agnese ; Scinto, Angelo Fedele ; Corsi, Domenico ; Carbognin, Luisa ; Bria, Emilio ; La Verde, Nicla ; Garufi, Carlo ; Di Stefano, Pia ; Mirabelli, Rossana ; Veltri, Enzo ; Paris, Ida ; Giotta, Francesco ; Lorusso, Vito ; Landucci, Elisa ; Ficorella, Corrado ; Roselli, Mario ; Adamo, Vincenzo ; Ricciardi, Giuseppina ; Russo, Antonio ; Valerio, Maria Rosaria ; Berardi, Rossana ; Pistelli, Mirco ; Cannita, Katia ; Zamagni, Claudio ; Garrone, Ornella ; Baldini, Editta ; Livi, Lorenzo ; Meattini, Icro ; Del Medico, Pietro ; Generali, Daniele ; De Maria, Ruggero ; Risi, Emanuela ; Ciliberto, Gennaro ; Villa, Alice ; Sperduti, Isabella ; Mazzotta, Marco ; Barba, Maddalena ; Giordano, Antonio ; Vici, Patrizia</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3535-aef57d2aeff3c09912eb9c484ba8adc6f203c925910b8eb88b92913fc2ae158b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Ado-Trastuzumab Emtansine - therapeutic use</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antibodies, Monoclonal, Humanized - therapeutic use</topic><topic>Antineoplastic Agents, Immunological - therapeutic use</topic><topic>Body Mass Index</topic><topic>Body size</topic><topic>Body weight</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - genetics</topic><topic>Breast Neoplasms - mortality</topic><topic>Chemotherapy</topic><topic>Disease Progression</topic><topic>ErbB-2 protein</topic><topic>Female</topic><topic>HER2‐positive metastatic breast cancer</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Medical prognosis</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Monoclonal antibodies</topic><topic>Multivariate analysis</topic><topic>Obesity</topic><topic>Obesity - complications</topic><topic>Overweight</topic><topic>Overweight - complications</topic><topic>pertuzumab</topic><topic>Progression-Free Survival</topic><topic>Quartiles</topic><topic>Receptor, ErbB-2 - genetics</topic><topic>Survival</topic><topic>Targeted cancer therapy</topic><topic>Trastuzumab</topic><topic>trastuzumab emtansine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Krasniqi, Eriseld</creatorcontrib><creatorcontrib>Pizzuti, Laura</creatorcontrib><creatorcontrib>Barchiesi, Giacomo</creatorcontrib><creatorcontrib>Sergi, Domenico</creatorcontrib><creatorcontrib>Carpano, Silvia</creatorcontrib><creatorcontrib>Botti, Claudio</creatorcontrib><creatorcontrib>Kayal, Ramy</creatorcontrib><creatorcontrib>Sanguineti, Giuseppe</creatorcontrib><creatorcontrib>Marchetti, Paolo</creatorcontrib><creatorcontrib>Botticelli, Andrea</creatorcontrib><creatorcontrib>Marinelli, Daniele</creatorcontrib><creatorcontrib>Gamucci, Teresa</creatorcontrib><creatorcontrib>Natoli, Clara</creatorcontrib><creatorcontrib>Grassadonia, Antonino</creatorcontrib><creatorcontrib>Tinari, Nicola</creatorcontrib><creatorcontrib>Tomao, Silverio</creatorcontrib><creatorcontrib>Tonini, Giuseppe</creatorcontrib><creatorcontrib>Santini, Daniele</creatorcontrib><creatorcontrib>Michelotti, Aandrea</creatorcontrib><creatorcontrib>Mentuccia, Lucia</creatorcontrib><creatorcontrib>Vaccaro, Aangela</creatorcontrib><creatorcontrib>Magnolfi, Emanuela</creatorcontrib><creatorcontrib>Gelibter, Alain</creatorcontrib><creatorcontrib>Magri, Valentina</creatorcontrib><creatorcontrib>Cortesi, Enrico</creatorcontrib><creatorcontrib>D’Onofrio, Loretta</creatorcontrib><creatorcontrib>Cassano, Alessandra</creatorcontrib><creatorcontrib>Cazzaniga, Marina</creatorcontrib><creatorcontrib>Moscetti, Luca</creatorcontrib><creatorcontrib>Fabbri, Agnese</creatorcontrib><creatorcontrib>Scinto, Angelo Fedele</creatorcontrib><creatorcontrib>Corsi, Domenico</creatorcontrib><creatorcontrib>Carbognin, Luisa</creatorcontrib><creatorcontrib>Bria, Emilio</creatorcontrib><creatorcontrib>La Verde, Nicla</creatorcontrib><creatorcontrib>Garufi, Carlo</creatorcontrib><creatorcontrib>Di Stefano, Pia</creatorcontrib><creatorcontrib>Mirabelli, Rossana</creatorcontrib><creatorcontrib>Veltri, Enzo</creatorcontrib><creatorcontrib>Paris, Ida</creatorcontrib><creatorcontrib>Giotta, Francesco</creatorcontrib><creatorcontrib>Lorusso, Vito</creatorcontrib><creatorcontrib>Landucci, Elisa</creatorcontrib><creatorcontrib>Ficorella, Corrado</creatorcontrib><creatorcontrib>Roselli, Mario</creatorcontrib><creatorcontrib>Adamo, Vincenzo</creatorcontrib><creatorcontrib>Ricciardi, Giuseppina</creatorcontrib><creatorcontrib>Russo, Antonio</creatorcontrib><creatorcontrib>Valerio, Maria Rosaria</creatorcontrib><creatorcontrib>Berardi, Rossana</creatorcontrib><creatorcontrib>Pistelli, Mirco</creatorcontrib><creatorcontrib>Cannita, Katia</creatorcontrib><creatorcontrib>Zamagni, Claudio</creatorcontrib><creatorcontrib>Garrone, Ornella</creatorcontrib><creatorcontrib>Baldini, Editta</creatorcontrib><creatorcontrib>Livi, Lorenzo</creatorcontrib><creatorcontrib>Meattini, Icro</creatorcontrib><creatorcontrib>Del Medico, Pietro</creatorcontrib><creatorcontrib>Generali, Daniele</creatorcontrib><creatorcontrib>De Maria, Ruggero</creatorcontrib><creatorcontrib>Risi, Emanuela</creatorcontrib><creatorcontrib>Ciliberto, Gennaro</creatorcontrib><creatorcontrib>Villa, Alice</creatorcontrib><creatorcontrib>Sperduti, Isabella</creatorcontrib><creatorcontrib>Mazzotta, Marco</creatorcontrib><creatorcontrib>Barba, Maddalena</creatorcontrib><creatorcontrib>Giordano, Antonio</creatorcontrib><creatorcontrib>Vici, Patrizia</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><jtitle>Journal of cellular physiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Krasniqi, Eriseld</au><au>Pizzuti, Laura</au><au>Barchiesi, Giacomo</au><au>Sergi, Domenico</au><au>Carpano, Silvia</au><au>Botti, Claudio</au><au>Kayal, Ramy</au><au>Sanguineti, Giuseppe</au><au>Marchetti, Paolo</au><au>Botticelli, Andrea</au><au>Marinelli, Daniele</au><au>Gamucci, Teresa</au><au>Natoli, Clara</au><au>Grassadonia, Antonino</au><au>Tinari, Nicola</au><au>Tomao, Silverio</au><au>Tonini, Giuseppe</au><au>Santini, Daniele</au><au>Michelotti, Aandrea</au><au>Mentuccia, Lucia</au><au>Vaccaro, Aangela</au><au>Magnolfi, Emanuela</au><au>Gelibter, Alain</au><au>Magri, Valentina</au><au>Cortesi, Enrico</au><au>D’Onofrio, Loretta</au><au>Cassano, Alessandra</au><au>Cazzaniga, Marina</au><au>Moscetti, Luca</au><au>Fabbri, Agnese</au><au>Scinto, Angelo Fedele</au><au>Corsi, Domenico</au><au>Carbognin, Luisa</au><au>Bria, Emilio</au><au>La Verde, Nicla</au><au>Garufi, Carlo</au><au>Di Stefano, Pia</au><au>Mirabelli, Rossana</au><au>Veltri, Enzo</au><au>Paris, Ida</au><au>Giotta, Francesco</au><au>Lorusso, Vito</au><au>Landucci, Elisa</au><au>Ficorella, Corrado</au><au>Roselli, Mario</au><au>Adamo, Vincenzo</au><au>Ricciardi, Giuseppina</au><au>Russo, Antonio</au><au>Valerio, Maria Rosaria</au><au>Berardi, Rossana</au><au>Pistelli, Mirco</au><au>Cannita, Katia</au><au>Zamagni, Claudio</au><au>Garrone, Ornella</au><au>Baldini, Editta</au><au>Livi, Lorenzo</au><au>Meattini, Icro</au><au>Del Medico, Pietro</au><au>Generali, Daniele</au><au>De Maria, Ruggero</au><au>Risi, Emanuela</au><au>Ciliberto, Gennaro</au><au>Villa, Alice</au><au>Sperduti, Isabella</au><au>Mazzotta, Marco</au><au>Barba, Maddalena</au><au>Giordano, Antonio</au><au>Vici, Patrizia</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real‐world evidence</atitle><jtitle>Journal of cellular physiology</jtitle><addtitle>J Cell Physiol</addtitle><date>2020-11</date><risdate>2020</risdate><volume>235</volume><issue>11</issue><spage>7900</spage><epage>7910</epage><pages>7900-7910</pages><issn>0021-9541</issn><eissn>1097-4652</eissn><abstract>Body mass index (BMI) is a main indicator of obesity and its association with breast cancer is well established. However, little is known in the metastatic setting, especially in HER2‐positive patients. We assessed the influence of BMI on clinical outcomes of patients treated with pertuzumab and/or trastuzumab emtansine (T‐DM1) for HER2+ metastatic breast cancer (mBC). BMI was addressed as a categorical variable, being classified on the basis of the following ranges, that is, 18.5–24.9, 25–29.9, and 30.0–34.9, namely, normal weight, overweight, and Class I obesity. The outcomes chosen were progression‐free survival to first‐line chemotherapy (PFS1) and overall survival (OS). Overall (N = 709), no impact of BMI was observed on PFS1 (p = .15), while BMI ≥ 30 was associated with worse OS (p = .003). In subjects who progressed to first line (N = 575), analyzing data across PFS1 quartiles and strata of disease burden, BMI predicted lower PFS1 in patients within the I PFS1 quartile and with the lowest disease burden (p = .001). Univariate analysis showed a detrimental effect of BMI ≥ 30 on OS for women within the I PFS1 quartile (p = .03). Results were confirmed in multivariate analysis. According to PFS1 quartiles a higher percentage of patients with high BMI and low disease burden progressed within 6 months of therapy. The effect of BMI on prognosis was also confirmed in multivariate analysis of OS for overall population. In our cohort, a BMI ≥ 30 correlated with worse OS in patients with HER2+ mBC who received pertuzumab and/or T‐DM1 but had no impact on PFS to first line. BMI predicted worse I PFS1 quartile.
We found that a body mass index ≥ 30 correlates with worse overall survival in HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine but had no impact on progression‐free survival (PFS) to first line. BMI predicted worse I PFS1 quartile.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>31943171</pmid><doi>10.1002/jcp.29445</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0001-7528-9783</orcidid><orcidid>https://orcid.org/0000-0003-4353-5390</orcidid><orcidid>https://orcid.org/0000-0001-9050-2917</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0021-9541 |
| ispartof | Journal of cellular physiology, 2020-11, Vol.235 (11), p.7900-7910 |
| issn | 0021-9541 1097-4652 |
| language | eng |
| recordid | cdi_proquest_journals_2444769363 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Ado-Trastuzumab Emtansine - therapeutic use Adult Aged Aged, 80 and over Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Agents, Immunological - therapeutic use Body Mass Index Body size Body weight Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - genetics Breast Neoplasms - mortality Chemotherapy Disease Progression ErbB-2 protein Female HER2‐positive metastatic breast cancer Humans Immunotherapy Medical prognosis Metastases Metastasis Middle Aged Monoclonal antibodies Multivariate analysis Obesity Obesity - complications Overweight Overweight - complications pertuzumab Progression-Free Survival Quartiles Receptor, ErbB-2 - genetics Survival Targeted cancer therapy Trastuzumab trastuzumab emtansine |
| title | Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real‐world evidence |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T03%3A21%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20BMI%20on%20HER2+%20metastatic%20breast%20cancer%20patients%20treated%20with%20pertuzumab%20and/or%20trastuzumab%20emtansine.%20Real%E2%80%90world%20evidence&rft.jtitle=Journal%20of%20cellular%20physiology&rft.au=Krasniqi,%20Eriseld&rft.date=2020-11&rft.volume=235&rft.issue=11&rft.spage=7900&rft.epage=7910&rft.pages=7900-7910&rft.issn=0021-9541&rft.eissn=1097-4652&rft_id=info:doi/10.1002/jcp.29445&rft_dat=%3Cproquest_cross%3E2444769363%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2444769363&rft_id=info:pmid/31943171&rfr_iscdi=true |